This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "AHFS Drug Information Book" – news · newspapers · books · scholar · JSTOR (January 2018) (Learn how and when to remove this template message)This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (January 2018) (Learn how and when to remove this template message)This article provides insufficient context for those unfamiliar with the subject. Please help improve the article by providing more context for the reader. (January 2018) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

The AHFS DI is one of several compendiums[1] approved by the Social Security Act (Section 1861(t)(2)(B)(ii)(I)) as a source of off-label anti-cancer drug use.[2][3] It was originally published in 1959 as the American Hospital Formulary Service (AHFS) by the American Society of Health-System Pharmacists.

It is also the only one left of the originally authorized compendiums.[4]


  1. ^ ElizabethHalpern, Hogan Lovells-; Langbein, Stuart M.; Manning, Meredith; Roberts, Beth L.; Lakhani, Ali (14 August 2015). "And then there were five: CMS approves Wolters Kluwer Lexi-Drugs® as the fifth recognized authoritative compendium | Lexology". Retrieved 2018-03-30.
  2. ^ "Medical Coverage Document". Centers for Medicare & Medicaid Services. Retrieved 6 January 2018.
  3. ^ Abernethy, Amy (October 2012). "Role of Compendia in Determining what Drugs are Reimbursed". National Science Foundation.
  4. ^ Butcher, Lola (2008-06-25). "Compendia Decisions Impact Off-Label Coverage". Oncology Times. 30 (12): 29–30. doi:10.1097/01.COT.0000326167.89228.b6. ISSN 0276-2234.

Further reading